Rapport Therapeutics (RAPP) Income from Continuing Operations (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Income from Continuing Operations of 143692000.0 for Q1 2026, up 98.82% year-over-year from 72271280.44 in Q1 2025, and up 2.65% quarter-over-quarter from 147602000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Income from Continuing Operations for 4 consecutive years, with 143692000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 98.82% year-over-year to 143692000.0; the TTM figure through Mar 2026 stood at 474112000.0 (up 96.13% YoY), while the FY2025 annual figure was 225322000.0, down 187.74% from the prior year.
- Income from Continuing Operations advanced to 143692000.0 in Q1 2026 per RAPP's latest filing, from 147602000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 6411000.0 in Q2 2023 and bottomed at 12209361000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 1065252416.67 across 4 years, with a median of 19050500.0 in 2024.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations sank 79809.42% — and 2026, when it surged 98.82%.
- Rapport Therapeutics' Income from Continuing Operations stood at 13519000.0 in 2023, then sank by 47.79% to 19980000.0 in 2024, then plunged by 638.75% to 147602000.0 in 2025, then rose by 2.65% to 143692000.0 in 2026.
- Business Quant data shows RAPP's Income from Continuing Operations at 143692000.0 in Q1 2026, 147602000.0 in Q4 2025, and 139286000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | -259.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -259.33 Mn |
| Mar 31, 2026 | -143.69 Mn |
| Dec 31, 2025 | -147.60 Mn |
| Sep 30, 2025 | -139.29 Mn |
| Jun 30, 2025 | -43.53 Mn |
| Mar 31, 2025 | -12.21 Bn |
| Dec 31, 2024 | -19.98 Mn |
| Sep 30, 2024 | -17.54 Mn |
| Jun 30, 2024 | -18.12 Mn |
| Mar 31, 2024 | -15.28 Mn |
| Dec 31, 2023 | -13.52 Mn |
| Sep 30, 2023 | -8.71 Mn |
| Jun 30, 2023 | -6.41 Mn |